Document is current
Any future updates will be listed below
-
Authors
McCulloch, John A.
Davar, Diwakar
Rodrigues, Richard R.
Badger, Jonathan H. https://orcid.org/0000-0002-5662-423X
Fang, Jennifer R. https://orcid.org/0000-0003-4930-4729
Cole, Alicia M. https://orcid.org/0000-0002-7792-2543
Balaji, Ascharya K.
Vetizou, Marie
Prescott, Stephanie M. https://orcid.org/0000-0002-0469-5255
Fernandes, Miriam R.
Costa, Raquel G. F.
Yuan, Wuxing
Salcedo, Rosalba
Bahadiroglu, Erol
Roy, Soumen
DeBlasio, Richelle N.
Morrison, Robert M. https://orcid.org/0000-0002-8421-8183
Chauvin, Joe-Marc
Ding, Quanquan
Zidi, Bochra
Lowin, Ava
Chakka, Saranya
Gao, Wentao
Pagliano, Ornella
Ernst, Scarlett J.
Rose, Amy
Newman, Nolan K.
Morgun, Andrey
Zarour, Hassane M. https://orcid.org/0000-0003-2525-2688
Trinchieri, Giorgio https://orcid.org/0000-0001-5892-7464
Dzutsev, Amiran K. https://orcid.org/0000-0003-0749-4149
-
Funding
Funding for this research was provided by:
Melanoma Research Foundation (Melanoma Breakthrough Foundation Breakthrough Consortium 2020)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA257265, P50 CA254865, R01 CA228181, R01 CA222203, P50 CA254865))
- License Information
-
More Information
Article History
Received: 26 March 2021
Accepted: 13 January 2022
First Online: 28 February 2022
Competing interests
: D.D. reports the following disclosures: Arcus, Bristol-Myers Squibb, Checkmate Pharmaceuticals, CellSight Technologies, Merck, GlaxoSmithKline/Tesaro (research support); Array Biopharma, Checkmate Pharmaceuticals, Finch, Incyte, Immunocore, Merck; Shionogi (consulting); and Vedanta Biosciences (scientific advisory board). H.M.Z. reports the following disclosures: Bristol-Myers Squibb, Checkmate Pharmaceuticals, GlaxoSmithKline (research support); Bristol-Myers Squibb, Checkmate Pharmaceuticals, GlaxoSmithKline, Vedanta (consulting). D.D., H.M.Z., J.A.M., R.R.R., G.T. and A.K.D. are inventors on a patent application (US patent no. 63/208,719) submitted by the University of Pittsburgh that covers methods to enhance checkpoint blockade therapy by the microbiome. The other authors declare no competing interests.
